CellCentric

Ares Genetics - a Vienna based startup - is revolutionizing how we address the global challenge of antimicrobial resistance (AMR).

To enable better infection control and more targeted patient care, Ares Genetics aims to provide unprecedented insight into AMR through next generation sequencing (NGS) and artificial intelligence (AI) powered solutions.
Innovative machine learning driven bioinformatics and the extensively curated ARESdb database comprehensively detect and interpret the genetic profile of pathogens.
Unlike conventional molecular assays, Ares Genetics solutions not only detect AMR markers but shed light on prevalence and diagnostic performance for these markers and predict how pathogens will respond to therapy.

Imprint: https://www.ares-genetics.com/imprint

Modern scientists are faced with a multitude of tasks, but many are not adequately supported in-house to perform all of them well.

To finance their research programmes researchers rely more and more on a mix of externally raised funds. But competition is increasing due to stagnating national research funds, which makes scientists look for alternatives on the international scene. Therefore, many internationally visible researchers in the life sciences turn to professional support to ensure their research proposals are competitive.

Proposals:
biolution has more than 12 years of experience in supporting life scientists successfully in the application for national and EU funds for research projects. Based on successful performance during FP7, biolution has become Austria’s premier service provider to apply for funding within the frame work programme or nationally.

Images:
biolution has assembled a visualisation pipeline based on the multidisciplinary expertise of its team and more than a decade of experience in explaining research. The inspiration was to generate affordable animations, which are rooted in scientific accuracy and extend into inspiring dynamic visualisations. It is our ambition to support researchers in their communication tasks with a dynamic representation of their favourite molecule or molecular process.
For our images follow us on Instagram: https://www.instagram.com/biolution_net/?hl=en

Quality Assistance S.A. is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products.

We assist our clients from candidate selection, through non-clinical and clinical studies, to marketing authorisation, using our state-of-the-art, product-dedicated expertise in analytical sciences.

For each customer and each project, we design customised solutions, define analytical protocols, develop and validate specific new analytical methods and perform characterisation, stability, pharmacokinetic, biomarker and immunogenicity studies as well as batch release testing, in order to evaluate the Quality, Safety and Efficacy of the given drugs.

Quality Assistance S.A. is an expert for the development of:
- Biologics (monoclonal antibodies, ADCs, proteins)
- New Chemical Entities, oligonucleotides, peptides
- Nanomedicine products
- Vaccines
- Cell-Based and Gene Therapy Medicinal Products

The company holds a unique position on the market with:
All its laboratories on one site (Donstiennes, Belgium)
- Bioanalysis (PK/TK/Immuno)
- Bioassays
- Biochemistry
- Chromatography
- Elemental Impurities
- Mass Spectrometry
- Microbiology
- Molecular Biology
- Protein Characterisation
200 highly qualified professionals
more than 35 years’ expertise at the forefront of analytical sciences.

Our core competencies are:
QUALITY (CMC)
- Development and validation of analytical methods
- Characterisation
- Stability studies
- Batch (release) testing
SAFETY/EFFICACY (Bioanalysis)
- Development and validation of bioanalytical methods
- PK/TK studies
- Immunogenicity studies
- Biomarker studies

The Quality Assistance environment is GMP, GLP and GCLP/GCP compliant.

Visit www.quality-assistance.com for more information

GEM FORLAB gives continuity to the experience of ABLE Biosciences as a global provider of scientific technology and services to the Life Science industry. It delivers solutions to companies of all size and shapes.
GEM FORLAB performs its activities by means of three technology areas:
Organic Chemistry
Mass Spectrometry & Proteomics
Cell and Molecular Biology & Immunoassay

ABLE Biosciences is the Test Facility GLP certified for small and large molecules quantitative analysis in biological matrices by means of Mass Spectrometry, Immunometric assays and qPCR and it is included in OsSC register of Private Laboratories qualified to perform analysis on samples derived from drug clinical trials (phase I-II-III) in compliance with GCP.

The Chemistry Unit provides all essential components for early drug discovery such as synthesis of chemical intermediates, process impurities, reference compounds, drug metabolites, and pro-drug; lead generation and optimization; bioconjugate chemistry; targeted molecules for MRI and others Molecular Imaging techniques.

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in H1 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in H1 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss Exchange and NASDAQ Capital Market, and trades under the ticker symbol "ADXN".